Leiomyosarcoma-Pipeline Review, H1 2016

Leiomyosarcoma-Pipeline Review, H1 2016


  • Products Id :- GMDHC7767IDB
  • |
  • Pages: 116
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Leiomyosarcoma-Pipeline Review, H1 2016', provides an overview of the Leiomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma

The report reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects

The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Leiomyosarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Leiomyosarcoma-Overview 8

Pipeline Products for Leiomyosarcoma-Comparative Analysis 9

Leiomyosarcoma-Therapeutics under Development by Companies 10

Leiomyosarcoma-Therapeutics under Investigation by Universities/Institutes 11

Leiomyosarcoma-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Leiomyosarcoma-Products under Development by Companies 14

Leiomyosarcoma-Products under Investigation by Universities/Institutes 15

Leiomyosarcoma-Companies Involved in Therapeutics Development 16

Advenchen Laboratories, LLC 16

BeiGene, Ltd. 17

Cell Medica Limited 18

Karyopharm Therapeutics, Inc. 19

Merck & Co., Inc. 20

Mirati Therapeutics Inc. 21

Novartis AG 22

Vicore Pharma AB 23

Leiomyosarcoma-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AL-3818-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

BGB-290-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

C-21-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

CMD-003-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

everolimus-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

mocetinostat-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

NOV-110501-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

pazopanib hydrochloride-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

pembrolizumab-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

selinexor-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Leiomyosarcoma-Recent Pipeline Updates 73

Leiomyosarcoma-Dormant Projects 113

Leiomyosarcoma-Discontinued Products 114

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

List of Figures

Number of Products under Development for Leiomyosarcoma, H1 2016 8

Number of Products under Development for Leiomyosarcoma-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Top 10 Targets, H1 2016 25

Number of Products by Stage and Top 10 Targets, H1 2016 25

Number of Products by Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27

Number of Products by Routes of Administration, H1 2016 29

Number of Products by Stage and Routes of Administration, H1 2016 29

Number of Products by Molecule Types, H1 2016 31

Number of Products by Stage and Molecule Types, H1 2016 31

List of Tables

Number of Products under Development for Leiomyosarcoma, H1 2016 8

Number of Products under Development for Leiomyosarcoma-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Leiomyosarcoma-Pipeline by Advenchen Laboratories, LLC, H1 2016 16

Leiomyosarcoma-Pipeline by BeiGene, Ltd., H1 2016 17

Leiomyosarcoma-Pipeline by Cell Medica Limited, H1 2016 18

Leiomyosarcoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 19

Leiomyosarcoma-Pipeline by Merck & Co., Inc., H1 2016 20

Leiomyosarcoma-Pipeline by Mirati Therapeutics Inc., H1 2016 21

Leiomyosarcoma-Pipeline by Novartis AG, H1 2016 22

Leiomyosarcoma-Pipeline by Vicore Pharma AB, H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Stage and Target, H1 2016 26

Number of Products by Stage and Mechanism of Action, H1 2016 28

Number of Products by Stage and Route of Administration, H1 2016 30

Number of Products by Stage and Molecule Type, H1 2016 32

Leiomyosarcoma Therapeutics-Recent Pipeline Updates, H1 2016 73

Leiomyosarcoma-Dormant Projects, H1 2016 113

Leiomyosarcoma-Discontinued Products, H1 2016 114

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advenchen Laboratories, LLC

BeiGene, Ltd.

Cell Medica Limited

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Mirati Therapeutics Inc.

Novartis AG

Vicore Pharma AB

Leiomyosarcoma Therapeutic Products under Development, Key Players in Leiomyosarcoma Therapeutics, Leiomyosarcoma Pipeline Overview, Leiomyosarcoma Pipeline, Leiomyosarcoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 128720
Site License
USD 4000 INR 257440
Corporate User License
USD 6000 INR 386160

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com